IL-11 still needs a pleiotropy tradeoff audit before universal-bottleneck promotion

IL-11 as a longevity candidate still needs a dedicated tradeoff audit

''结论'': IL-11 currently remains the strongest immune/inflammation longevity candidate because it has direct mouse healthspan/lifespan benefit. However, a critic should not upgrade it to a universal longevity bottleneck without first auditing its pleiotropy.

''主要反证点'':
# IL-11 is implicated in regeneration programs, at least in zebrafish adult heart/fin/scale regeneration and pro-regenerative niche maintenance.
# IL-11 also has documented roles in bone formation/remodeling and skull/bone phenotypes; adult systemic inhibition could therefore carry repair or skeletal costs.

''筛选规则'': Any cytokine candidate with lifespan benefit but known roles in regeneration or structural homeostasis needs a tradeoff audit before being treated as a universal bottleneck.

''Implication'': The next critic step is not to ask whether IL-11 works, but whether its benefit survives a serious adult-system safety and repair-cost review.